Align: Selling Innovation to Late Adopters
Dentistry and orthodontics have been largely untouched by significant recent product development, and thus have not attracted much interest from medical device venture investors. Align Technology emerged from an unlikely source--two second-year Stanford business students with no previous start-up experience who were able to attract major venture backers. The founders' idea was that, by using advanced product design and manufacturing processes, the company could produce the Invisalign system of removable, clear plastic dental appliances that, for certain orthodontic patients, particularly adults--a large untapped market--could take the place of traditional metal braces. The company's founders invested heavily in direct-to-consumer marketing that resulted in patients favoring the product before many doctors were familiar with it. After a successful IPO, Align's channel problems, along with other missteps, drove the company's stock down to the one-dollar range. A new management team has restructured the company and implemented a more focused strategy. For Align, traditional braces are now no longer the enemy. Instead, the company promotes Invisalign as another tool in the orthodontists' and dentists' armamentarium, an approach that appears to be capturing support among customer groups not known for embracing new technology.
You may also be interested in...
The past couple of years have witnessed the formation of more than a dozen companies focused on taking a portfolio of very early stage medical devices to the next level. With good ideas and connections, device industry executives, as an alternative to joining operating companies are increasingly joining incubators where they can keep their hands in device company creation over a number of projects. Whether you call these companies incubators or accelerators, they all share the goal of filling a gap between technology and company creation, and funding. Accelerators can help early stage concepts get the hearing they normally might not get either in the venture capital community, which is prepared to take on clinical and market risk but not technological risk, or large companies, which are focused on maintaining existing businesses. In fact, for certain kinds of broadly-enabling platform technologies that cut across clinical specialties, the incubator/accelerator model makes a lot of sense.
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.